p16 gene overexpression in mouse bladder carcinomas

M Asamoto1, T Hori, H Baba-Toriyama

  • 1Chemotherapy Division, National Cancer Center Research Institute, Tokyo, Japan.

Cancer Letters
|June 10, 1998
PubMed

Insights

This study found that while gene deletion is not involved in mouse bladder cancer, abnormalities in p16 gene expression may play a role. Further research into p16 gene expression in bladder carcinomas is warranted.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Deletion at 9p21 is common in human bladder carcinomas.
  • The p16 gene, a potential tumor suppressor, is located in the 9p21 region.
  • Investigating p16 gene alterations in mouse bladder cancer models is crucial.

Purpose of the Study:

  • To investigate loss of heterozygosity (LOH) and expression of the p16 gene in mouse bladder carcinomas.
  • To assess the impact of normal cell contamination on LOH analysis using xenografts.
  • To determine the role of p16 gene alterations in mouse bladder carcinogenesis.

Main Methods:

  • Analysis of p16 gene LOH in primary mouse bladder carcinomas and xenografts.
  • Evaluation of p16 gene expression levels in tumor samples.
  • Use of microsatellite polymorphisms to differentiate between mouse strains (B6C3F1 and CD-1(ICR)) and assess contamination effects.

Main Results:

  • No loss of heterozygosity (LOH) at the p16 locus was detected in mouse bladder carcinomas or xenografts.
  • Surprising overexpression of the p16 gene was observed in all primary mouse bladder carcinomas.
  • Careful tumor tissue sampling confirmed negligible effects of normal cell contamination on LOH analysis.

Conclusions:

  • Gene deletion of p16 is not implicated in mouse bladder carcinogenesis.
  • Abnormalities in p16 gene expression are suggested to be involved in mouse bladder cancer development.
  • The findings highlight the importance of p16 expression rather than deletion in this cancer model.